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ABSTRACT
The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the
induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block
complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produced in
our laboratory. So far, no proper IgG2/4 control antibody has been available for controlled validation of
IgG2/4 antibody functions. Here, we describe the design of a recombinant control antibody (NHDL),
which was generated by combining the variable light (VL) and heavy (VH) chains from two unrelated
specificities. NHDL was readily expressed and purified as a stable IgG2/4 antibody, and showed no
detectable specificity toward any putative antigen present in human or porcine blood. The approach of
artificial VL/VH combination may be adopted for the design of other recombinant control antibodies.
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Antibodies are the fastest growing class of biologics, and more
than 60 antibody-based drugs have been approved for clinical
use.1 In addition, hundreds of antibodies are undergoing pre-
clinical and clinical testing for the treatment of a variety of
diseases and disorders, including inflammation and cancer,
and novel mechanisms of action and delivery strategies are
being explored.1 These antibodies bind their cognate antigen
and induce Fc-mediated effector functions through the
engagement of complement or Fc receptors, which may result
in antibody-dependent complement-mediated cell lysis, anti-




similarities in amino acid composition, where minor differences
between themaffect their ability to engage anantigen and to induce
effector functions.2 IgG1 and IgG3 are themost efficient triggers of
effectorfunctions,andsinceIgG1hasalongerserumhalf-life,itisthe
preferredsubclassforthedevelopmentoftherapeuticantibodies.2,3In
addition, the composition of the biantennary N-glycan structures
attached to Asn297 of the CH2 domain determines the potency of
effector functions throughactivationofFcγRsandcomplementC1,
and,therefore,glycoengineeringcanbeusedtotailorIgGmolecules.4,5
When the main aim of a therapeutic antibody is to block
the function of the targeted antigen, it may be desirable to
design the antibody with reduced ability to induce effector
functions, while retaining long serum half-life. This may be
achieved, for example, by means of aglycosylated IgG or site-
specific mutations.5–7 Saunders has written a comprehensive
review of this topic.8 As IgG2 and IgG4 are the least effector
potent subclasses, they can be combined in the design of
“effector-less” antibodies, like IgG2m4 and IgG2σ, in which
IgG4 key residues have been introduced in the IgG2 Fc back-
bone by point mutations,9,10 or recombinant IgG2/4 CH
hybrid antibodies (in short IgG2/4), where the CH1 and
hinge region from IgG2 are fused to the CH2 and CH3
domains from IgG4.11–14
One such IgG2/4 antibody is the anti-human complement
factor C5 antibody eculizumab (Soliris®), which is approved by
the United States Food and Drug Administration (FDA) for
treatment of the rare diseases paroxysmal nocturnal hemoglobi-
nuria, atypical hemolytic uremic syndrome and myasthenia
gravis. These diseases are all caused by dysregulation of the
complement system,14–16 which is part of the body’s first line
of defense. It is activated by both pathogenic and endogenous
danger signals, and acts by opsonization, anaphylatoxy, and
signal transduction. Complement activation is tightly controlled
and dysregulation may cause rare and common diseases, which
in some cases may be life-threatening.17–19 Thus, eculizumab
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and other complement-inhibitory drugs are not only critical for
treatment of such diseases, but also important tools for studying
them.20–23
Since the IgG2/4 backbone is already used in a marketed
product, we constructed two such antibodies in our laboratory
for neutralization of human and porcine CD14 in different
sepsis models, and reported the results of studies exploring
their properties.12,24,25 CD14 is a cofactor of several Toll-like
receptors (TLRs), including TLR2 and TLR4, that are
the second branch of innate immunity against pathogenic
and endogenous danger. CD14 facilitates pattern recognition
of mainly acylated structural components like Gram-negative
bacterial lipopolysaccharide (LPS), and induces the expression
of proinflammatory cytokines and type I interferons through
TLR signaling.26–29 Recently, increased plasma levels of a 13
kDa soluble CD14 subtype (sCD14-ST; presepsin) have
emerged as an early sepsis marker.30 Although the blocking
of CD14 has been shown to be beneficial in various experi-
mental sepsis models, the strategy has failed in clinical trials.
Due to signaling crosstalk between CD14/TLRs and comple-
ment, a more potent therapeutic strategy to treat sepsis, how-
ever, seems to be the combined inhibition of CD14 and
complement, as successfully demonstrated in mice and por-
cine models.25,31,32 This approach may also be effective in the
treatment of acute sterile inflammatory conditions like trauma
and ischemia-reperfusion injury.32,33
As for any experimental set-up, for studies where IgG2/4
CH hybrid antibodies are attractive tools, proper controls are
needed. Earlier, we designed a putative IgG2/4 control anti-
body (raNIP) directed toward the hapten hydroxy-3-iodo-
5-nitrophenylacetic acid.12 However, this antibody was
expressed at low titers and induced unwanted adverse effects
when applied ex vivo in human and porcine whole blood.
Here, we aimed to construct a novel IgG2/4 control antibody
with improved properties, i.e., high expression level and struc-
tural integrity, as well as minimum effector functions and
adverse effects.
Results
Construction of NHDL: an IgG2/4 control antibody
We hypothesized that the construction of an IgG2/4 control
antibody could be achieved by combining the cDNA encoding
the variable light and heavy domains from antibodies of two
unrelated specificities. To test this, we took advantage of
a panel of previously designed IgG2/4 antibodies, namely
r18D11, rMil2, and raNIP, which encode anti-human CD14
(clone 18D11), anti-porcine CD14 (clone Mil2) and anti-NIP
(aNIP) specificities, respectively.12 All possible combinations
of two vectors encoding their variable light (VL) or variable
heavy (VH) regions, upstream of the respective light chain
(pLNOk) or heavy chain (pLNOH) constant regions, were
transiently transfected into adherent HEK293E cells. Three
days post transfection, three of six combinations were
shown to yield secreted antibodies (Figure 1a). It appeared
that the VL with anti-human CD14 specificity (clone 18D11)
was most suited for VH/VL combinations, and yielded
expressed antibodies that included any of the tested VH.
Based on this observation, and in order to avoid two anti-
CD14 specificities in the same antibody molecule, we chose to
proceed with the evaluation of the VH/VL hybrid bearing the
aNIP VH and the 18D11 VL (Figure 1b), named NHDL, as
a putative IgG2/4 control antibody.
Figure 1. Composition of IgG2/4 control antibody NHDL.
A, The expression of all possible VL/VH combinations for IgG2/4 control antibody generation was tested by transient transfection of HEK293E cells with different
combinations of the two separate DNA plasmids encoding the light (VL+CL; pLNOk) or heavy (VH+CH; pLNOH) chains of anti-NIP (aNIP), anti-porcine CD14 (Mil2) or
anti-human CD14 (18D11) specificities. Cell culture supernatant (SN) was harvested 3 days post transfection and IgG titer was estimated as µg/mL using ELISA (n = 3;
mean ± S.E.M.). B, Schematic model of NHDL, a mouse/human chimeric IgG2/4 antibody. The constant regions, i.e., human kappa light chain (hCκ; blue), human IgG2
CH1/hinge (light gray) and human IgG4 CH2-3 (dark gray), are identical for the IgG2/4 CH hybrid antibodies described so far, i.e., NHDL, r18D11, rMil2, and eculizumab.
The murine variable regions of NHDL are derived from two different specificities, i.e., VH of anti-NIP (yellow) and VL of anti-CD14 clone 18D11 (orange). The model
was generated using Adobe Illustrator.
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When NHDL was expressed following a previously established
12-day batch-batch protocol for medium scale production in
HEK293E cells,12 it was produced with a similar profile over
time as the other IgG2/4 antibodies (Figure S1a). Further,
NHDL (21.6 ± 6.2 µg/106 cells) was produced in similar amounts
as 18D11 (30.0 ± 5.4 µg/106 cells), but in fourfold higher amounts
when compared with raNIP (5.7 ± 1.1 µg/106 cells) (Figure S1b).
Also, NHDL was easily obtained by Protein A-assisted affinity
chromatography (Figure S1c), which enabled us to perform
a thorough characterization of this putative control antibody.
Structural integrity of NHDL compared to other IgG2/4
antibodies
The structural integrity of NHDL was evaluated by SDS-PAGE,
size exclusion chromatography (SEC) and differential scanning
fluorimetry (DSF), and compared to other IgG2/4 antibodies, i.e.,
anti-human C5 (eculizumab), anti-NIP (raNIP), anti-human
CD14 (r18D11), and anti-porcine CD14 (rMil2). Non-reducing
SDS-PAGE analysis revealed that all IgG2/4 antibodies migrated
as one major band corresponding to molecular weights above 150
kDa, which is expected for N-glycosylated monomeric IgG
(Figure 2a). This was confirmed by SEC, where one main peak
was detected for all antibodies (Figure 2b). However, additional
peaks were observed for r18D11, rMil2 and raNIP, indicating the
presence of non-covalent oligomers (r18D11, rMil2) or higher-
order aggregates (raNIP). In addition, r18D11 eluted somewhat
earlier than the other IgG2/4 antibodies, likely due to distinct
structural properties of this particular antibody, which can affect
retention on the SEC column.
Next, thermal unfolding was measured using DSF where
the recombinant IgG2/4 antibodies exerted melting tempera-
tures (Tm) in the range of 68.5°C to 64.9°C, similar to com-
mercial eculizumab, which has a Tm of 68.2°C (Figure 2c). In
contrast to NHDL, and any other IgG2/4 antibody, the DSF
profile of raNIP showed a high fluorescence background
signal below 40°C.
Taken together, the exchange of anti-NIP VL in raNIP with
anti-human CD14 VL of r18D11, combined with anti-NIP VH,
gave rise to a more efficiently produced and structurally more
stable recombinant IgG2/4 molecule, namely NHDL.
NHDL as control for anti-human CD14 r18D11
Next, it was essential to test for the remaining antigen-binding
properties of NHDL. This was done by incubating equimolar
amounts of recombinant soluble human CD14 (sCD14) with
NHDL or anti-CD14 antibody r18D11 before samples were
applied to native polyacrylamide gel electrophoresis, which
revealed complex formation between sCD14 and r18D11 but
not NHDL (Figure 3a). To confirm this ex vivo, up to 10 µg/mL
R-phycoerythrin (PE)-conjugated NHDL or r18D11 were
Figure 2. Structural integrity of NHDL compared to other IgG2/4 antibodies.
a, The IgG2/4 antibodies NHDL, raNIP, and r18D11, all purified from the supernatant of transiently expressing HEK293E cells, as well as rMil2 and eculizumab were
subjected to non-reducing SDS-PAGE (4–15%) using Precision Plus ProteinTM standard as protein ladder. b, Size exclusion chromatography profiles of the indicated
IgG2/4 antibodies were normalized to a relative absorbance maximum of 1.0 and displayed as an overlay. Fractions of monomeric single IgG molecules were
contained by the main peaks between 11.4 mL and 12.5 mL, while IgG oligomers or aggregates appeared earlier and as minor peaks. Note that r18D11 eluted slightly
earlier than the other IgG2/4 antibodies. c, Monomeric IgG2/4 antibody fractions prepared by SEC were subjected to differential scanning fluorimetry and melting
curves were generated for temperatures between 20⁰C to 80⁰C. Dye incorporation increases as proteins disassemble, reaching a maximum of around 70⁰C prior to
aggregation and decrease of the signal. The derived melting temperatures were 67.7⁰C for NHDL, 64.9⁰C for r18D11, 68.5⁰C for rMil2, and 68.2⁰C for eculizumab. The
melting curve of raNIP showed unusual high background fluorescence below 40⁰C, in the so-called native state.
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incubated with fresh human whole blood, and cell surface bind-
ing to human CD14 was monitored using flow cytometry
(Figure 3b). While a concentration-dependent increase in fluor-
escence signals, indicating binding, was detected for r18D11, no
such signals were obtained for NHDL. In line with this, when
added, unlabeled NHDL did not compete for the binding of the
PE-conjugated anti-CD14 antibody (Figure 3b).
In accordance with CD14 being the LPS receptor, binding of
r18D11 to CD14 has been shown to block LPS-induced inflam-
matory cytokine release from responding blood cells.12,28 When
comparing r18D11 with NHDL ex vivo in humanwhole blood, no
effect of NHDL on the CD14-dependent interleukin (IL)-6 release
was detected (Figure 3c). Thus, NHDL does not bind or block
human CD14 and can be used to control the activity of r18D11.
Blood plasma protein binding by IgG2/4 antibodies
In order to exclude the possibility that NHDL specifically
recognized any antigen contained by human blood plasma,
we compared the immunoprecipitation of plasma proteins by
NHDL with that by r18D11, and eculizumab. The antibodies
were coupled to magnetic beads, followed by incubation with
human plasma and a washing procedure. Immunoprecipitated
proteins were subjected to mass spectrometry and a sequence
database search. In total, 66 proteins, including immunoglo-
bulins and transport proteins, were shown to potentially bind
at least one of the antibodies, including a bead-coupled con-
trol IgG with irrelevant specificity (anti-human CD3 mouse
IgG1). Cluster analyses revealed that the immunoprecipitation
profiles for the IgG2/4 antibodies were rather similar (Figure
S2a). Only 14 of the identified proteins were non-IgG
sequences with peptide-spectrum match scores (#PSM;
a signal quality measure) above 10 and higher for NHDL
than for the control IgG. Spectrum peak area intensities of
the peptides contained by the immunoprecipitated proteins
were used to quantitatively compare potential binding by
NHDL, r18D11 and eculizumab (Figure 3d). As expected,
among the proteins that were immunoprecipitated by eculi-
zumab and r18D11, their cognate antigens human C5 and
CD14, respectively, were identified with the highest intensi-
ties. Importantly, for NHDL, none of the identified proteins,
including CD14 and C5, were immunoprecipitated from
human plasma with a considerably higher score than for the
other IgG2/4 antibodies (Figure 3d). This indicates that
human plasma does not contain any putative antigen for
NHDL.
Figure 3. Test of binding and blocking activity of human CD14 by NHDL.
a, Different molar ratios of purified antibody (r18D11 or NHDL) and recombinant soluble CD14 (sCD14) (given as antigen to antibody) were incubated in vitro and
subsequently separated by native PAGE in absence of SDS. The antigen-antibody complex formation became apparent as a newly formed band and a reduction in or
loss of the bands corresponding to free antibody or free sCD14. All three bands are indicated by arrows. b, Human whole blood was incubated with 10–10,000 ng/mL
of PE-conjugated NHDL or r18D11. Binding was analyzed by flow cytometry and given as mean fluorescence intensity (MFI). For competitive binding, blood was pre-
incubated with 15 µg/mL unconjugated r18D11 or NHDL prior to the addition of the PE-conjugated antibodies. Results are shown as MFI (n = 3; mean ± S.E.M.). The
MFI (330 ± 9.8) of a PE-conjugated mIgG1 control antibody is indicated by the dotted line. c, Whole human blood was incubated with PBS or 100 ng/mL upLPS in
absence or presence of 15 µg/mL or 30 µg/mL r18D11 or NHDL for 120 min at 37⁰C. Plasma IL-6 levels were analyzed by Bioplex technology and are given in pg/mL
(n = 3; mean ± S.E.M.). d, human plasma (a pool of n = 6) was incubated with Dynabeads®-coupled NHDL, r18D11, eculizumab, or a control antibody (Ctrl IP; anti-
CD3 mIgG1), and co-immunoprecipitated proteins were identified using mass spectrometry. The results are shown for non-IgG sequences with #PSM>10 and peak
area values larger for NHDL than for the control antibody (Ctrl IP). The unfiltered results are displayed as a heatmap in Figure S2a.
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NHDL as control for anti-human C5 eculizumab and
anti-porcine CD14 rMil2
Next, we addressed whether NHDL could be used as a control
antibody for the IgG2/4 antibodies eculizumab and rMil2. Using
an ELISA established to quantify binding of eculizumab to human
C5 in human serum or plasma,34 we confirmed the immunopre-
cipitation data showing that NHDL did not bind C5 (Figure 4a).
To test for C5 inhibition, human plasma was incubated with heat-
aggregated IgG (HAIgG) in the presence or absence of NHDL and
eculizumab, followed by measuring C5-dependent formation of
the soluble terminal complement sC5b-9 complex (TCC) (Figure
4b). In contrast to eculizumab, TCC generation was not abolished
in the presence of NHDL. Thus, NHDL proved inert with respect
to both C5 binding and blocking.
To compare NHDL with rMil2 in porcine CD14 binding and
inhibition, fresh porcine blood was drawn and subjected to flow
cytometry and immunoprecipitation-tandemmass spectrometry
(MS/MS) for binding assays, as well as to the ex vivowhole blood
model (Figure 4c and S3). In flow cytometry, neither binding of
NHDL to porcine white blood cells (Figure S3a) nor competition
of the positive signal for fluorescein isothiocyanate (FITC)-
conjugated Mil2 binding to porcine CD14 positive blood cells
were detected (Figure 4c). Also, binding of NHDL to porcine
blood plasma proteins was tested by immunoprecipitation fol-
lowed by MS/MS (Figure S3b). Here, no putative antigen could
be identified for NHDL, whereas rMil2 readily co-
immunoprecipitated with its antigen, porcine CD14.
Further, opposed to rMil2, NHDL did not reduce the
Escherichia coli (E. coli)-induced, partially CD14-dependent
IL-8 release in porcine whole blood (Figure 4d), but rather
increased the response somewhat, which is addressed below.
Together, NHDL did not bind porcine CD14 and did not
block its effects in whole blood.
Nip-binding by NHDL
As NHDL contains a VH, which is specific for the synthetic
hapten NIP, potential binding was tested using ELISA, where
bovine serum albumin (BSA)-conjugated NIP was immobi-
lized in a microtiter plate and incubated with up to 10 µg/mL
NHDL. In contrast to anti-NIP mIgG1, no binding of NHDL
was detected (Figure S4).
NHDL production from stably transfected CHO-K1SP cells
Since NHDL proved suitable as an IgG2/4 control antibody, we
aimed to establish a protocol for large-scale production by stably
transfected Chinese ovary hamster (CHO)-K1SP cells.
Compared to transient expression in HEK293E cells, expression
titers were increased by 500 to 1000-fold, yielding 13 mg NHDL
and 28 mg r18D11 per 106 CHO-K1SP cells (Figure 5a), or
≥1 mg IgG2/4 antibody per mL supernatant, within 14 days of
cultivation.
Expression system-dependent IgG N-glycosylation profiles
The expression system used for recombinant IgG production
may affect antibody properties due to differential
Figure 4. Test of binding and blocking of human C5 and porcine CD14 by NHDL.
a, Increasing amounts (2.5–50 µg/mL) of recombinant antibody (rAb), i.e., NHDL or eculizumab, were incubated with a human serum pool that naturally contains C5,
and C5-bound antibody (rAb-C5 complex) was quantified as µg/mL by ELISA according to a standard curve using eculizumab. b, Complement activation in a human
serum pool in the presence or absence of 1 mg/mL heat-aggregated IgG (HAIgG) and 200 µg/mL NHDL or eculizumab (Ec.) was measured as TCC formation using
ELISA. Data are given as complement arbitrary units (CAU/mL) for one representative experiment. c, Competitive binding of FITC-conjugated Mil2 to porcine whole
blood cells in presence of 10, 50 or 100 µg/mL NHDL or rMil2 was measured by flow cytometry. A FITC-conjugated mIgG2b antibody served as a negative control
(Ctrl). Results are shown as MFI (n = 3; mean ± S.E.M.). d, E. coli-induced (1 x 105/mL) porcine plasma IL-8 release was measured in the absence or presence of 50 or
100 µg/mL NHDL or rMil2 using Bioplex technology. The results are given as pg/mL (n = 3; mean ± S.E.M.).
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N-glycosylation (for reviews, see refs. 4, 34, 35).4,35,36 Therefore,
N-glycosylation profiles of the CHO- and HEK293E-produced
IgG2/4 antibodies were mapped using LC-MS (Table S1 and
Figure S5). Cell-type specific differences were revealed regard-
ing the degree of terminal galactosidation of 4-N-acetyl-
glucosamine-1-fucose-3-mannose (4GlcNac-1Fuc-3Man), the
core structure (G0) of typical Asn297-attached N-glycans
(Table S1). Despite being the major N-glycan attached in all
preparations, non-galactosidated G0 constituted a much higher
portion of all detected N-glycans for NHDL and r18D11
derived from CHO cells compared to those from HEK293E
cells (i.e., 79.1% and 75.3% compared to 54.4% and 49.0%,
respectively). Notably, differences in the N-glycosylation pro-
files for different IgG2/4 antibodies produced from the same
cell line were only minor (Table S1).
Expression system-dependent IgG structural integrity
No difference in IgG integrity could be observed between
NHDL and r18D11 derived from CHO cells compared to
HEK293E cells, as they migrated with similar bands in non-
reducing SDS-PAGE (Figure S6A) and gave very similar melt-
ing curves in DSF analyses (Figure S6b and c).
Binding of IgG2/4 antibodies to effector molecules
To address whether the differences in the N-glycan profiles
affected the binding of the IgG2/4 antibodies to effectormolecules,
we performed ELISA where titrated amounts of the antibodies
were coated followed by the addition of selected human Fcγ
receptors or C1q. The results revealed that CHO-produced
NHDL and r18D11 did not bind human FcγRI, FcγRIIIa, and
C1q, while modest binding to human FcγRIIa was observed
(Figure 5b). In contrast, HEK293E-produced NHDL bound
human FcγRI weakly, while HEK293E-produced r18D11 did not
(Figure 5B), which is in line with previous observations for
HEK293E-produced r18D11.12 In addition, no major differences
in pH-dependent binding to the human and porcine versions of
neonatal Fc receptor (FcRn) were detected between the recombi-
nant IgG2/4 antibodies produced from CHO and HEK293E cells
(Figure S7).
Inflammatory responses to the IgG2/4 antibodies
Next, we ruled out an influence of the choice of host cell line on
the CD14-blocking effect of r18D11 in human whole blood chal-
lengedwith 100 ng/mL upLPS, while proving that both CHO- and
HEK293E-produced NHDL were inactive (Figure 5c). However,
Figure 5. Characterization of CHO-produced NHDL and r18D11.
A, The expression of recombinant NHDL and r18D11 by stably transfected CHO-K1SP cell pools (fed-batch) was compared to transient expression by HEK293E cells
(batch-batch). Cell culture supernatants were analyzed for IgG levels using ELISA. Results are given as single value mg IgG per E06 CHO cells (n = 1), and mean mg
IgG ± S.E.M. per E06 HEK293E cells for NHDL (n = 3) and r18D11 (n = 6). B, Binding of increasing concentrations of CHO- and HEK293E-produced NHDL or r18D11 to
recombinant human C1q or recombinant human Fcγ receptors hFcγRI, hFcγRIIa, and hFcγRIIIa at pH 7.4 was measured by ELISA. As a positive control, a recombinant
human IgG1 antibody (bevacizumab (Avastin®), Roche) was included in the analysis. The results are shown as relative units for the absorbance at 450 nm (n = 2;
mean ± S.D.). C, Human whole blood was incubated with CHO- or HEK293E-produced r18D11 (1.5, 15 and 30 µg/mL) or NHDL (15 µg/mL) in the presence of 100 ng/
mL upLPS. As controls, 15 µg/mL r18D11 or NHDL were incubated in the presence of PBS, only. Plasma IL-6 was measured using Bioplex technology. Data are given
as pg/mL (n = 2; mean ± S.D.).
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in the same experiment, we observed that HEK293E-produced
NHDL, and to a lesser extent r18D11, induced IL-6 release in
absence of upLPS, while CHO-produced NHDL did not to the
same extent (Figure 5c). Earlier, we had observed an increased IL-
8 release in E. coli-challenged porcine blood in the presence of
HEK293E-produced NHDL (Figure 4d). This prompted us to
evaluate putative cytokine release and complement activation
induced by CHO-produced IgG2/4 antibodies when added to
whole human or porcine blood (Figure 5c and S8). Indeed, there
was minor induction of IL-6 and TCC in human blood (Figure 5c
and S8A) and of any tested cytokine and TCC in porcine blood
(Figures S8B and S8C). However, these effects were similar for all
IgG2/4 antibodies, including commercial eculizumab.
Taken together, NHDL was produced in CHO cells at high
titers, with unaffected thermal stabilities and only minor
effector functions, which were comparable to other IgG2/4
antibodies, including eculizumab. Therefore, NHDL should
be a suitable IgG2/4 control antibody for ex vivo testing in
human and porcine whole blood as well as in in vivo porcine
models.
Discussion
Here, we presented a novel IgG2/4 control antibody, called
NHDL, which carries the variable regions of two different
specificities, and exerts no antigen-binding capacity.
Therefore, it can be applied as a negative control for antibo-
dies with the same IgG2/4 CH hybrid backbone in in vitro
assays.
The antigen-binding domain of NHDL was designed as an
artificial VL/VH hybrid, containing the VL of the human CD14-
specific antibody clone 18D11 and the VH of a synthetic
hapten-specific antibody (anti-NIP).12 Here, we showed that
their combination destroyed both specificities, which was
a prerequisite for NHDL being suitable as a control antibody.
Antibody variable regions are important determinants not only
of antigen specificity but also of structural integrity.37–40 Our study
demonstrated that artificial VL/VH combinations can result in
readily expressed, properly assembled antibody molecules with
structural integrity, as NHDL was expressed as a stable, mono-
meric IgG2/4 antibody.
NHDL was more inert with respect to the induction of
effector functions than the previously described control anti-
body raNIP.12 In raNIP, the VL and VH regions are identical
in amino acid sequence, and one may speculate whether this
led to the formation of aggregates and low expression titers.12
However, raNIP is only unstable in the IgG2/4 kappa back-
ground, while the same pairing of variable sequences is readily
expressed as recombinant human IgG1 kappa and IgG3
lambda antibodies using the same HEK293E cell-based
expression system.41,42 Therefore, it remains to be seen
whether artificial VL/VH combinations may result in properly
folded antibodies of any human IgG subclass or format, as
well as IgGs from different species.
Further, the generation of artificial non-antigen-binding
IgG based on VL/VH combination may appear straightforward
and cost-efficient when separate heavy and light chain-
encoding plasmids for the production of monospecific anti-
bodies are readily available, as was the case with this study.
Although this strategy has limitations, the scientific commu-
nity has accumulated extensive knowledge about antigen-
antibody binding and produced a wide array of engineered
antibodies,43,44 which may provide alternative routes to gen-
erate non-binding control antibodies. However, as antigen-
binding capacity can affect an antibody’s pharmacokinetic
properties,45 differences in clearance and tissue distribution
of non-binding control antibodies compared to the binding
IgG may occur in vivo, regardless of the design strategy.
The combination of human IgG2- and IgG4-derived
sequences in one hybrid backbone is ingeniously suited when
effector functions are to be avoided, since it has very low
potential to activate complement and Fcγ receptors.9,10,12–14
As elegantly summarized by Saunders, substantial research
has been performed on how to minimize effector functions
by specific amino acid mutations of human IgG antibodies,
and various promising IgG2 and IgG4 variants have been
generated.8 To our knowledge, three antibodies with the parti-
cular IgG2/4 CH hybrid backbone consisting of IgG2 CH1/
hinge and IgG4 CH2/CH3 have been reported, i.e., the US FDA-
approved anti-human C5 antibody eculizumab, anti-human
CD14 antibody r18D11, and anti-porcine CD14 antibody
rMil2.12,15,20 NHDL proved to be inert with respect to binding
and blocking these antigens ex vivo in human and porcine
whole blood, as well as to nonspecific binding to any potential
antigen contained by human or porcine blood. As such, NHDL
is a proper control for epitope neutralization and effector
functions of IgG2/4 CH hybrid antibodies, at least in human
and pig disease models.
Importantly, C5 and CD14 are upstream inflammatory med-
iators, and inhibition of these, either alone or in combination,
has substantial potential in various diseases.46 Eculizumab has
been approved for the treatment of three complement-
dependent diseases, and may potentially be applied to other
common and rare diseases due to the increasingly appreciated
clinical significance of the complement system.22,47 Also, the
therapeutic potential of CD14 inhibition has been demonstrated
in various models of acute systemic inflammation, especially in
combination with complement inhibition.46
From this and a previous study, we know that IgG2/4
antibodies may induce a modest degree of complement acti-
vation, which can be measured as TCC formation in human
and porcine blood, as well as pro-inflammatory cytokine
release in porcine blood.12 It appears that these effects are
dependent on cell line-specific N-glycosylation of light and/or
heavy chains, which is known to influence effector molecule
binding in addition to antibody stability, pharmacokinetics,
and pharmacodynamics.4,35 Both TCC and cytokine levels
were largely reduced when NHDL and r18D11 were expressed
by CHO cells instead of HEK293E cells. Also, CHO-produced
NHDL did not bind human FcγRI, while HEK293E-produced
NHDL was found to have some affinity. Notably, eculizumab
is produced in murine NS0 cells, while upcoming eculizumab
biosimilars are produced in CHO cells.48
When IgG2/4 antibodies were expressed in CHO and
HEK293E, the main difference in N-glycosylation of Asn297 in
the CH2 domain was the lower degree of terminal galactosylation
of 4-N-acetylglucosamine-1-fucose-3-mannose (4GlcNac-1Fuc-
3Man) in CHO compared to HEK293E cells. Non-galactosylated
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4GlcNac-1Fuc-3Man has also been shown to be common for
other IgG subclasses expressed in CHO cells, i.e., IgG1.49 Higher
degree of N-glycosylation, in particular the presence of terminal
galactose moieties, may increase antibody complement-
dependent cytotoxicity as well as FcγRIIIa-mediated ADCC.36
Therefore, the lower degree of galactosidation when expressed
from CHO compared to HEK293E cells may account for
reduced induction of cytokine release and TCC formation by
CHO-produced NHDL and r18D11.
Previously, we showed that HEK293E-produced IgG2/4
antibodies, including raNIP, did not bind human C1q and
FcγRI, IIb, IIIa, and IIIb in vitro.12 Importantly, CHO-
produced IgG2/4 antibodies did not bind FcγRIIIa, which
appears to be a major mediator of therapeutic antibody
efficacy.36 Both HEK293E- and CHO-produced IgG2/4 anti-
bodies, however, had some affinity toward activating
FcγRIIa, which may result in limited induction of effector
functions.49 Notably, FcγRIIa binding has been reported to
be independent of the presence of terminal galactose,36
which is in line with our study results. Nevertheless, gly-
coengineering of either the antibody or the expressing host
cell line may be applied to render therapeutic IgG2/4 anti-
bodies even more “effector-less”.49–51
The residual effector functions of IgG2/4 antibodies need
to be taken into account. However, when an anti-CD14 IgG2/
4 antibody is combined with complement factor C3 or C5
inhibitory reagents, which we propose for treatment of certain
acute inflammatory events,33 the adverse effect on comple-
ment activation will most likely be suppressed by the inhibi-
tors. NHDL will, in any case, provide a proper control
antibody in both in vitro experiments and in vivo animal
models, as long as the pharmacokinetics are similar. Future
studies will reveal whether it also can be used as a placebo
reagent in clinical studies.
Materials and methods
Blocking antibodies
The mouse/human chimeric IgG2/4 anti-human and por-
cine CD14 antibodies r18D11 and rMil2 were constructed
and produced in our laboratory as previously reported.12
The same applies to the hapten 4-hydroxy-3-iodo-5-nitro-
phenylacetic acid (NIP)-specific control antibody raNIP.
Anti-human CD14 mouse antibody clone 18D11 was pur-
chased from Diatec (Diatec Monoclonals AS, Oslo,
Norway). The humanized IgG2/4 anti-human C5 antibody
eculizumab (Soliris®) was obtained from Alexion
Pharmaceuticals Inc. (Cheshire, CT, USA). For flow cyto-
metry analyses, the rIgG2/4 antibodies NHDL, r18D11 and
rMil2, as well as anti-human CD14 clone 18D11 and ecu-
lizumab were conjugated with PE using Lightning-Link®
R-Phycoerythrin Conjugation Kit (Innova Biosciences,
703–0010). FITC-conjugated anti-porcine CD14 mouse
antibody clone Mil2 and a FITC-conjugated mIgG2b con-
trol antibody were purchased from AbD Serotec (Bio-Rad
AbD Serotec Ltd., MCA1218F).
Construction of plasmid DNA for expression of
recombinant IgG2/4 antibody NHDL
Variable gene retrieval and cloning of constant regions of the
recombinant mouse-human chimeric IgG2/4 antibodies were
described in detail previously.12,42 Briefly, two plasmids con-
taining oriP, pLNOH2 and pLNOK, were constructed for each
recombinant antibody, encoding the heavy and the kappa light
chain, respectively. The variable regions for the NHDL anti-
body were retrieved from monoclonal mouse antibodies raised
against (1) a hapten (NIP) for the heavy chain, and (2) human
CD14 (clone 18D11) for the light chain. Thus, the name NHDL
stands for NIP heavy chain (NH) and 18D11 light chain (DL).
The sequence for the human IgG2/4 hybrid constant region of
the heavy chain was retrieved from the literature.13
Analytical scale NHDL expression and purification
Adherent HEK293-EBNA (HEK293E) cells were thawed and
subcultured for two passages at 5% CO2 and 37°C in DMEM
containing 4.5 g/L L-glucose (Lonza, BE12–614F) and supple-
mented with 10% Fetal Bovine Serum Superior EU (Biochrom,
Merck Millipore, BCHRS0615), 50 µg/mL G418 (Invitrogen,
10131–019), 4 mM L-glutamine (Lonza, BE17–605E), 10,000
U/mL penicillin, and 10,000 mg/mL streptomycin (Lonza,
DE17–602E). Cells were transiently transfected with
Lipofectamine 2000 (Invitrogen, 11668–019) according to the
manufacturer’s protocol using a heavy chain-encoding plasmid
(pLNOk) to light chain-encoding plasmid (pLNOH) ratio of
1:1. As a transient batch-batch procedure, cells were kept in
serum-free OptiMEM (Invitrogen, 31985–047) for 12 days, and
the antibody was harvested from the supernatant every
third day. The supernatant was cleared from cell debris by
centrifugation (5 min, 250 xg) and vacuum filtration through
0.22 µm PES (TPP Techno Plastic Products AG, 99250) prior to
antibody purification (see below). The antibody titer was esti-
mated by standard ELISA using Goat Anti-Human Ig Fc pooled
antisera (SouthernBiotech), either unconjugated as coat (2047–-
01) or horseradish peroxidase (HRP)-conjugated as capture
(2047–05). The chromogenic readout was achieved by the addi-
tion of hydrogen peroxide as a substrate in ABTS buffer (Sigma-
Aldrich, A9941–100TAB), and the signal was detected at 405
nm using an MRX plate reader from Dynex Technologies
(Chantilly, VA). The antibody-containing cell culture superna-
tant was concentrated using Vivacell 100 PES concentrators
with a 30K MWCO (Sartorius, VC1022). The antibody was
purified using NAb Protein A Plus spin columns (Pierce
Biotechnology, 89948) following the manufacturer’s instruc-
tions. Final buffer exchange to phosphate-buffered saline
(PBS) pH7.4 and concentration to up to 1 mg/mL was done
using concentrators with a 20K MWCO (Pierce Biotechnology,
87750).
SDS-PAGE, native PAGE, and western blot
The materials for PAGE were purchased from Bio-Rad (Bio-
Rad Laboratories, Inc., Hercules, CA). The antibody prepara-
tion was monitored by standard non-denaturing SDS-PAGE
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using Mini-PROTEAN Precast Gels (4–15%, 456–1084) and
Tris-Glycine SDS buffer (161–0772). Antibody-antigen com-
plexes were run on native PAGE using Mini-PROTEAN
Precast Gels (4–15%) and Tris-Glycine buffer (161–0734).
Gels were stained using Biosafe Coomassie G250 (161–0786).
For immunoblotting, proteins were transferred onto
Protran NC membrane (0.45 µm; Amersham, 10600003) and
incubated with goat anti-human kappa light chain antibody
(SouthernBiotech, 2060–01) prior to HRP-conjugated rabbit
anti-goat IgG antibody (SouthernBiotech, 6160–05). ECL was
performed with SuperSignal®West Dura Extended Duration
substrate (Pierce, 34075) and detected using ChemiDoc XRS+
(Bio-Rad Laboratories, Inc., Hercules, CA).
In vitro complex formation with recombinant sCD14
IgG2/4 antibodies were incubated 10 min at room temperature
(RT) with recombinant soluble human CD14 (sCD14; ~50
kDa), either at molar excess of either molecule or at equimolar
amounts, and run on native PAGE at 125 V for 90 min.
Recombinant sCD14 was constructed as C-terminally octa-
His-tagged protein, lacking the C-terminal eight amino acids
(aa368–375) in order to avoid glycosylphosphatidylinositol
anchoring, as described by Hailman et al.52 Soluble CD14 was
expressed into cell culture medium of transiently transfected
(Lipofectamine 2000) HEK293E cells, and purified using
HisPurTM Ni-NTA Spin Purification Kit (Pierce, 88228).
Expression and purity of sCD14 were confirmed by SDS-
PAGE and immunoblot using mouse anti-hexa His antibody
(clone 13/45/31–2; Pierce, MA1-4806).
Size exclusion chromatography
Protein-A purified recombinant IgG2/4 antibodies were fractio-
nized by SEC using a Superdex 200 10/300 column (GE
Healthcare, 28-9909-44) connected to anÄKTA-FPLC instrument
(GE Healthcare, Buckinghamshire, UK). Fractions containing
monomeric recombinant IgG2/4 variants were up-concentrated
using Amicon® Ultra centrifugal filters (Millipore, UFC205024).
Differential scanning fluorimetry
DSF was performed using a LightCycler® 480 RT-PCR instru-
ment (Roche Diagnostics Norge AS, Oslo, Norway). Sypro®
Orange (Sigma-Aldrich, S5692) was mixed (1:1000) with pur-
ified antibody (0.1 mg/mL) in 25 µL PBS. Samples were run in
triplicates in LightCycler® 480 multi-well plates 96 (Roche,
04729692001). The RT-PCR instrument was programmed to
ramp the temperature from 20⁰C to 95⁰C within 30 min, after
an initial period of 10 min at 20⁰C. Data were collected every
0.5⁰C using 450 nm excitation and 568 nm emission filters. Data
transformation and analysis were performed using the DSF
analysis protocol as described by Niesen et al.53 To calculate
the Tm values, the lowest temperature value at steady state
(before protein starts to unfold) and the temperature value at
highest fluorescence intensity (protein is completely unfolded)
were used.
Whole blood model of inflammation according to
Mollnes et al.32
Fresh human or porcine whole blood from three independent
individuals was anti-coagulated with 50 µg/mL lepirudin
(Refludan®, Pharmion, Copenhagen, Denmark) and incubated
in 1.8 mL Cryo Tube vials (Nunc, 377267) for 120 min at 37⁰C
on a rock’n’roller with either sterile PBS with MgCl2 and CaCl2
(Sigma-Aldrich, D8662) or an inflammation-inducing agent.
Here, we used 100 ng/mL ultrapure LPS from E. coli O111:B4
(InvivoGen, tlrl-3pelps) for human blood and 1x105/mL heat-
inactivated E. coli strain LE392 (ATCC 33572) for porcine blood.
The incubation was further done in the presence or absence of
increasing or fixed amounts of the IgG2/4 control antibody
NHDL, raNIP, anti-human CD14 (r18D11), and anti-porcine
CD14 (rMil2). To stop the response, 10 mM (human blood) or
20 mM (porcine blood) EDTA was added, and plasma was
gained by 15 min centrifugation at 3220 xg and 4°C.
Enzyme immunoassays
Human and porcine plasma cytokines were quantified using
Luminex technology using Bio-Plex® Multiplex Immunoassays
from Bio-Rad and ProcartaPlexTM Multiplex Immunoassays
from eBioscience, respectively. Complement activation in porcine
samples was measured as soluble terminal C5b-9 complement
complex (sC5b-9, TCC) generation using standard ELISA and
complement arbitrary units (CAU)/mL as readout.54 Briefly,
ascites containing monoclonal anti-human C9 neoepitope anti-
body, clone aE11,55 was used for capture and biotinylated (EZ-
Link® NHS-SS-Biotin; Pierce, 21331) anti-human C6 (Quidel,
A219) for detection. Further incubations with streptavidin-
coupled peroxidase (GE Healthcare, RPN1231) and H2O2 in
ABTS buffer generated a specific signal, which was recorded at
405 nm using an MRX plate reader from Dynex Technologies.
Antibody titers of IgG2/4 were revealed by standard sandwich
ELISA using polyclonal goat anti-human IgG Fc antibody
(Southern Biotech) for capture (unconjugated, 2047–01) as well
as for detection (HRP-conjugated, 2047–05).
Immunoprecipitation for mass spectrometry
Purified IgG2/4 antibodies (100 µg NHDL, r18D11, and rMil2)
and commercial anti-C5 eculizumab (100 µg) were coupled to
10 mg magnetic beads using DynabeadsTM Antibody Coupling
Kit (NovexTM, LifeTechnologies, 143-11D). Coupling efficiency
was 85–99%, according to unbound IgG estimated by ELISA.
Plasma pools were generated from fresh human (n = 6) or porcine
(n = 9) blood, anti-coagulated with 50 µg/mL lepirudin
(Refludan®), by centrifugation at 3000 xg for 20 min or 10 min,
respectively. For immunoprecipitation, plasma was diluted in 4x
Vol PierceTM IP lysis buffer (87787) containing PierceTM Protease
and Phosphatase Inhibitor Mini Tablets (88668). Further, 10 µg
bead-coupled IgG were incubated with 500 µL diluted human or
porcine plasma pools rotating overnight at 4⁰C. To control for
technical artifacts and putative nonspecific or intrinsic binding of
murine IgG to human and porcine plasma proteins, immunopre-
cipitation using a commercial magnetic bead-coupled anti-human
CD3 mouse IgG1 antibody (Dynabeads® CD3, Dynal Biotech
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ASA) was performed in parallel. The putative antibody-antigen
complexes were washed twice on a magnetic stand with 0.5 mL IP
lysis buffer and eluted with 50 µL Laemmli buffer containing 5%
β-mercaptoethanol by boiling 5 min at 95⁰C. Of the latter, 10 µL
was briefly separated by SDS-PAGE, before the gel was Coomassie
stained and the stained broad bands were cut for downstream
mass spectrometry sample preparation.
Mass spectrometry and data processing
Gel pieces were subjected to in-gel reduction, alkylation, and
tryptic digestion using 6 ng/μL trypsin (Promega, V511A).
OMIX C18 tips (Varian, Inc., A57003100k) were used for
sample clean-up and concentration. Peptide mixtures contain-
ing 0.1% formic acid were loaded onto an EASY-nLC1000
system (Thermo Fisher Scientific, Waltham, MA) and EASY-
Spray column (C18, 2 µm, 100 Å, 50 µm, 50 cm; Thermo
Fisher Scientific, ES803). Peptides were fractionated using
a 2 – 100% acetonitrile gradient in 0.1% formic acid over 50
min at a flow rate of 200 nL/min. The separated peptides were
analyzed using a Q-Exactive mass spectrometer (Thermo
Fisher Scientific). Data were collected in data-dependent
mode using a Top10 method. The raw data were processed
using the Proteome Discoverer 2.0 software (Thermo
Scientific). The fragmentation spectra were searched against
the Swissprot_2015_05 database using an in-house Mascot
server (Matrix Sciences, UK). Peptide mass tolerances used
in the search were 10 ppm, and fragment mass tolerance was
0.02 Da. Peptide ions were filtered using a false discovery rate
(FDR) set to 1% for peptide identifications.
For hierarchical clustering, raw data were processed by the
MaxQuant software v 1.5.0.15 with the integrated Andromeda
search engine using the label-free quantification (LFQ)
method. MS/MS data were searched against the Uniprot
human and porcine databases from 2015. An FDR ratio of
0.01 was needed to give a protein identification. Hierarchical
clustering was done with log2 transformed LFQ intensities
using average Euclidian distance.
Flow cytometry analyses
For competitive assays, fresh human or porcine lepirudin
anti-coagulated blood (100 µL per test) was pre-incubated 15
min at RT with increasing amounts of unconjugated IgG2/4
control antibody NHDL and unconjugated anti-human CD14
(clone r18D11) or anti-porcine CD14 (clone rMil2) antibo-
dies, respectively. Afterward, the blood was incubated for an
additional 15 min at RT with PE-conjugated anti-human
CD14 (clone 18D11, 15 µg/mL) or FITC-conjugated anti-
porcine CD14 (clone Mil2, 100 µg/mL) antibody. A FITC-
conjugated mIgG2b control antibody was included to control
for background fluorescence in porcine samples.
For direct binding assays, fresh human or porcine lepirudin
anti-coagulated blood (100 µL per test) was incubated with
increasing amounts of R-PE-conjugated NHDL for 15 min at
RT. The results were compared to binding of R-PE-conjugated
anti-human CD14 (r18D11; 10 ng/mL to 10 µg/mL) or anti-
porcine CD14 (rMil2; 10 and 50 µg/mL) antibodies. As controls
in human blood, four blood samples were pre-incubated with
15 µg/mL unconjugated NHDL or r18D11 prior to the addition
of 10 µg/mL PE-conjugated antibody. As negative control in
porcine blood, one blood sample was incubated with the irrele-
vant PE-conjugated anti-human CD14 antibody (r18D11).
Subsequently, red blood cells were lysed and remaining blood
cells were fixed using Lyse/Fix solution (BDBiosciences, 558049)
prior to analyses on an LSRII flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) using FACS Diva 7 software. Human
monocyte and porcine granulocyte populations were selected
based on the forward scatter/side scatter dot plot, and antibody
binding was recorded as mean fluorescence intensity (MFI).
Complement C5 binding and activation in human serum
For C5 binding analyses, 156 µL of a human serum pool was
incubated for 30 min at 37⁰C with 40 µL rIgG2/4 isotope
control antibody NHDL or anti-C5 IgG2/4 antibody eculizu-
mab at final concentrations of 1.5 µg/mL to 50 µg/mL.
C5 binding was quantified using a recently established
enzyme-immunoassay for the detection of eculizumab-C5
complexes,34 using an anti-C5 antibody as capture and an
HRP-conjugated anti-human IgG4 antibody for detection.
For C5 blocking analyses, 156 µL of a human serum pool
was incubated for 30 min at 37⁰C with 40 µL PBS, NHDL or
eculizumab (200 µg/mL final concentration), and 4 µL PBS or
heat-aggregated IgG (HAIgG; 1 mg/mL final concentration).
Complement activation was measured as TCC generation in
CAU/mL as described above for Enzyme immunoassays.
Production scale expression and two-step purification of
rIgG2/4 antibodies
CHO-K1SP cell pools stably expressing NHDL or r18D11
were generated by Genscript Inc. (Piscataway, NJ, USA).
The suspension culture was kept at 37°C, 5% CO2, >90%
relative humidity and 120 rpm using a Kuehner LT-X shaking
incubator (Adolf Kühner AG, Birsfelden, Switzerland) at
50 mm rotating diameter. Freshly thawed cells were resus-
pended at 4 x 105/mL in CD CHO medium (GibcoTM, Life
Technologies, 10743–011) containing L-Methionine sulfoxi-
mine (Merck Millipore, GSS-1015-F) and anti-clumping
agent (GibcoTM, Life Technologies, 01-0057DG), and culti-
vated for three passages using sterile 125 mL Erlenmeyer
flasks (EF) (Corning, CLS431143-50EA). For fed-batch pro-
duction culture, 4 × 107 cells in 100 mL CD FortiCHO
medium (InvitrogenTM, Life Technologies, A11483-01) con-
taining L-methionine sulfoximine and anti-clumping agent
were cultivated in 500 mL EF (Corning, CLS431145-25EA)
for a period of 14 days. CHO CD EfficientFeed™ B Liquid
Nutrient Supplement (InvitrogenTM, Life Technologies,
A10240-01) was added at 10% (v/v) every second day for 8
days, before continuation for another 6 days without feed.
On day 14, cell viability was still above 50% and cell culture
supernatant was harvested by centrifugation and filtration
(0.22 µm PES; TPP). The protocol can be scaled up using
one or more 1000 mL EF (Corning, CLS431147-25EA) or
TubeSpin® Bioreactor 600 (TPP, 87600) and 200 mL to
320 mL expression medium ± feed per flask. The antibody
was purified on an NGC Quest 10 (Bio-Rad Laboratories, Inc.,
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Hercules, CA) in two steps: 1) Protein-A affinity chromato-
graphy using Foresight UNOsphere SUPrA (Bio-Rad,
732–4749), and 2) preparative SEC using HiPrep 26/60
Sephacryl S-300HR (GE Healthcare, 17-1196-01). Fractions
containing monomeric recombinant IgG2/4 antibody were
up-concentrated using Amicon® Ultra centrifugal filters
(Millipore, UFC205024) or Vivacell® 100 PES centrifugal con-
centrators (Sartorius, VC1022) and stored at −80°C.
FcγR binding by ELISA
ELISA 96-well plates were coated with 100 mL of titrated
amounts (10,000.0–4.6 ng/mL) of HEK293E- or CHO-
produced NHDL or r18D11 in PBS (Sigma-Aldrich, D8537-
500ML) and incubated overnight at 4°C. After washing, 1 µg/
ml GST-tagged hFcγRI, hFcγRIIa, and FcγRIIIa in 4% skim
milk (PanReac AppliChem, 0830,5000) in PBS containing
0.05% Tween20 (Sigma-Aldrich, P1379_500ML) (PBST)
were incubated for 1 h at RT before being washed as above.
Bound receptors were detected using an HRP-conjugated goat
anti-GST Ab (Rockland Immunochemicals Inc., 600-103-200)
diluted 1:8000 in 4% skim milk/PBST. After washing, 100 µL
TMB substrate (Millipore, CL07-1000ML) was added to each
well, and reactions were stopped by adding 100 µL 1 M HCl.
The absorbance was measured at 450 nm using a Sunrise
spectrophotometer (Tecan Trading AG, Switzerland).
Animals
Porcine blood samples were drawn from healthy Norwegian
landrace piglets (Sus scrofa domesticus), prior to their use in
independent in vivo studies.
Abbreviations
CAU complement arbitrary units
CD14 cluster of differentiation 14
CH constant heavy chain
CHO Chinese ovary hamster
DSF differential scanning fluorimetry
E. coli Escherichia coli
ELISA enzyme-linked immunosorbent assay
FcγR Fc gamma receptor
LC-MS liquid chromatography – mass spectrometry
MFI mean fluorescence intensity
NIP 4-hydroxy-3-iodo-5-nitrophenylacetic acid
PSM peptide spectrum matches
S.D. standard deviation
S.E.M. standard error of the mean
SEC size exclusion chromatography
TLR Toll-like receptor
Tm melting temperature
VH variable heavy chain
VL variable light chain
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